Ctni-69. A First-In-Human Feasibility Study To Evaluate The Safety Of Selective Yttrium-90 Endovascular Radiotherapy In Patients With Recurrent Gbm: Interim Results From The Frontier Trial

Samdeep Mouli,Sameer Ansari,Erik Middlebrooks,John Boockvar,Jonathan Weinstein,Yafell Serulle,Nicholas Butowski,Kazim Narsinh,Paul Kennedy,Amanda Eldridge,Franco Basarabescu,Kianna Elahi-Gedwillo,Riad Salem,Roger Stupp

DOI: https://doi.org/10.1093/neuonc/noae165.0436

2024-11-29

Neuro-Oncology

Abstract:BACKGROUNDYttrium-90 (Y90) microsphere treatment is an FDA-approved endovascular radiotherapy for Hepatocellular Carcinoma; however, extra-hepatic experience is limited. The FRONTIER trial (NCT05303467) is a first-in-human study conducted under an IDE from the FDA evaluating the safety and feasibility of intra-arterial Y90 endovascular radiotherapy in patients with recurrent glioblastoma (rGBM). METHODSThe primary endpoint is the incidence of treatment-related limiting toxicities through 30 days, in 12 patients with rGBM. Eight subjects (50% male) with non-dominant hemisphere rGBM have been enrolled to date, with 6 patients reported herein. The treatment region, encompassing the recurrent lesion, excluding eloquent regions, and defined using cerebral angiography-MRI fusion, was selectively targeted with 40±4Gy. Immediate post-treatment imaging included MRI to evaluate acute treatment-related effects and Y90-PET to evaluate the absorbed dose distribution. Neurological assessments were performed pre- and post-treatment. Analysis of post-contrast T1w enhancing tissue volume (T1w vol ) inside and outside the treated region was performed longitudinally. RESULTSAll patients tolerated the procedure well and were discharged the following day. No decrease in neurological function and no limiting toxicities were reported through 30 days. Post-treatment MRI revealed no device-related acute ischemia or hemorrhage. Mean absorbed dose to the treatment region was 42.1±2.4Gy, within 3% of the targeted value, suggesting technical feasibility. Mean tumor absorbed dose within the treatment region was 65.1±22.6Gy most likely due to increased tumor perfusion in the treatment region. A reduction in T1w vol at 2m was observed in 4/6 patients, with the remaining 2 patients showing increased T1w vol . Disease progression by T1w vol occurred more rapidly outside the treatment region than within. All patients received subsequent therapy, with 2 patients receiving surgery 82 and 120 days post Y90 treatment. CONCLUSIONInterim results in this first-in-human feasibility study demonstrated technical feasibility and no limiting toxicities through 30 days. Enrollment is ongoing. These data warrant additional investigation.

oncology,clinical neurology